NYSE: NNVC Could Be 2026's Defining Biotech Story ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from NanoViricides, Inc.
NanoViricides (NYSE: NNVC) may be the Breakout Biotech of 2026 with NV-387 Poised to Revolutionize Antiviral Therapy Across Measles, Respiratory Viruses, MPox, and Biodefense Markets NanoViricides (NYSE: NNVC) is a clinical-stage biotech positioned to redefine antiviral therapy with its lead drug NV-387, a broad-spectrum, dual-action antiviral that not only destroys viruses before they infect cells but also protects critical organs like the lungs from immune-mediated damage. With resurgent measles outbreaks across the U.S., NV-387 has already demonstrated 130% increased survival and lung protection in humanized animal models, is safe and well-tolerated in Phase I trials, and is available as patient-friendly oral gummies. The drug’s unique “Re-Infection Inhibition” nanotechnology makes it highly selective yet broadly effective, targeting measles, respiratory viruses, COVID-19, RSV, influenza, H5N1 bird flu, MPox, and smallpox, positioning NNVC as a versatile antiviral powerhouse ready to address multi-billion-dollar global markets. NNVC is executing a dual-track, rapid clinical development strategy to accelerate NV-387 toward broad use. Track 1 focuses on a Phase II trial against MPox in Congo, already ethically approved, with potential U.S. biodefense funding from BARDA. Track 2 targets respiratory viruses through an adaptive “basket-type” Phase II trial in India, including influenza, RSV, and coronaviruses, potentially starting in Winter 2026 and leading to focused U.S. trials by 2027. With strong clinical data, broad-spectrum applications, and multi-billion-dollar market potential, NV-387 is poised to become the go-to antiviral solution for urgent outbreaks and epidemic preparedness. Investors seeking the next biotech breakout of 2026 should watch NNVC closely. See why NNVC’s NV-387 is ready to transform antiviral therapy and capture a rapidly growing, urgent market. |
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $6,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 11/14/2025. Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.
|
|
